keyword
https://read.qxmd.com/read/22538770/mutation-profiling-identifies-numerous-rare-drug-targets-and-distinct-mutation-patterns-in-different-clinical-subtypes-of-breast-cancers
#21
JOURNAL ARTICLE
Libero Santarpia, Yuan Qi, Katherine Stemke-Hale, Bailiang Wang, Elliana J Young, Daniel J Booser, Frankie A Holmes, Joyce O'Shaughnessy, Beth Hellerstedt, John Pippen, Tatiana Vidaurre, Henry Gomez, Vicente Valero, Gabriel N Hortobagyi, W Fraser Symmans, Giulia Bottai, Angelo Di Leo, Ana M Gonzalez-Angulo, Lajos Pusztai
The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from fine needle aspirations of 267 stage I-III breast cancers. These tumor specimens typically consisted of >80% neoplastic cells. We examined 28 genes for 163 known cancer-related nucleic acid variations by Sequenom technology...
July 2012: Breast Cancer Research and Treatment
https://read.qxmd.com/read/22521545/breast-cancer-side-population-cells-and-abcg2-expression
#22
JOURNAL ARTICLE
K M Britton, R Eyre, I J Harvey, K Stemke-Hale, D Browell, T W J Lennard, A P Meeson
Recurrent metastatic breast cancer may arise in part due to the presence of drug resistant adult stem cells such as Side Population (SP) cells, whose phenotype has been demonstrated to be due to the expression of ABCG2. We hypothesised that SP may be identified in Fine Needle Aspirates (FNAs) and their presence may be determined by expression of ABCG2 in breast tumours. SP and non-side population cells (NSP) were isolated using dual wavelength flow cytometry combined with Hoechst 33342 dye efflux and analysed for expression of ABCG2 and chemoresistance...
October 1, 2012: Cancer Letters
https://read.qxmd.com/read/22487539/perifosine-plus-docetaxel-in-patients-with-platinum-and-taxane-resistant-or-refractory-high-grade-epithelial-ovarian-cancer
#23
JOURNAL ARTICLE
Siqing Fu, Bryan T Hennessy, Chaan S Ng, Zhenlin Ju, Kevin R Coombes, Judith K Wolf, Anil K Sood, Charles F Levenback, Robert L Coleman, John J Kavanagh, David M Gershenson, Maurie Markman, Kristine Dice, Adrienne Howard, Jane Li, Yang Li, Katherine Stemke-Hale, Mary Dyer, Edward Atkinson, Ed Jackson, Vikas Kundra, Razelle Kurzrock, Robert C Bast, Gordon B Mills
OBJECTIVES: On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer. METHODS: Patients with pathologically confirmed high-grade epithelial ovarian cancer (taxane resistant, n=10; taxane refractory, n=11) were enrolled. Peripheral blood samples and tumor biopsies were obtained and (18)F-FDG-PET and DCE-MRI scans were performed for pharmacodynamic and imaging studies...
July 2012: Gynecologic Oncology
https://read.qxmd.com/read/22422301/systematic-analysis-of-genotype-specific-drug-responses-in-cancer
#24
JOURNAL ARTICLE
Nayoung Kim, Ningning He, Changsik Kim, Fan Zhang, Yiling Lu, Qinghua Yu, Katherine Stemke-Hale, Joel Greshock, Richard Wooster, Sukjoon Yoon, Gordon B Mills
A systematic understanding of genotype-specific sensitivity or resistance to anticancer agents is required to provide improved patient therapy. The availability of an expansive panel of annotated cancer cell lines enables comparative surveys of associations between genotypes and compounds of various target classes. Thus, one can better predict the optimal treatment for a specific tumor. Here, we present a statistical framework, cell line enrichment analysis (CLEA), to associate the response of anticancer agents with major cancer genotypes...
November 15, 2012: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/22419365/detection-algorithm-for-the-validation-of-human-cell-lines
#25
JOURNAL ARTICLE
Névine Eltonsy, Vivian Gabisi, Xuesong Li, K Blair Russe, Gordon B Mills, Katherine Stemke-Hale
Cell lines are an important tool in understanding all aspects of cancer growth, development, metastasis and tumor cell death. There has been a dramatic increase in the number of cell lines and diversity of the cancers they represent; however, misidentification and cross-contamination of cell lines can lead to erroneous conclusions. One method that has gained favor for authenticating cell lines is the use of short tandem repeats (STR) to generate a unique DNA profile. The challenge in validating cell lines is the requirement to compare the large number of existing STR profiles against cell lines of interest, particularly when considering that the profiles of many cell lines have drifted over time and original samples are not available...
September 15, 2012: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/22151725/interactions-between-tumor-cells-and-microenvironment-in-breast-cancer-a-new-opportunity-for-targeted-therapy
#26
REVIEW
Shreya Mitra, Katherine Stemke-Hale, Gordon B Mills, Sofie Claerhout
Breast cancer remains the leading cause of morbidity and second-leading cause of death in women. Despite efforts to uncover new targeted therapies, a vast number of women die due to refractory or recurrent breast tumors. Most breast cancer studies have focused on the intrinsic characteristics of breast tumor cells, including altered growth, proliferation, and metabolism. However, emerging research suggests that the tumor microenvironment can substantially affect relapse rates and therapeutic responses. In this review, we discuss the interactions between the tumor and microenvironment in breast cancer, with regard to mutational profiles and altered metabolism that could serve as potential therapeutic targets...
March 2012: Cancer Science
https://read.qxmd.com/read/22130161/correlation-of-nras-mutations-with-clinical-response-to-high-dose-il-2-in-patients-with-advanced-melanoma
#27
JOURNAL ARTICLE
Richard W Joseph, Ryan J Sullivan, Robyn Harrell, Katherine Stemke-Hale, David Panka, George Manoukian, Andrew Percy, Roland L Bassett, Chaan S Ng, Laszlo Radvanyi, Patrick Hwu, Michael B Atkins, Michael A Davies
The purpose of this study is to identify clinical and molecular characteristics of melanoma patients that predict response to high-dose interleukin-2 (HD IL-2) to improve patient selection for this approved but toxic therapy. We reviewed the records of 208 patients with unresectable stage III/IV melanoma treated with HD IL-2 at the University of Texas M.D. Anderson Cancer Center (n=100) and the Beth Israel Deaconess Medical Center (n=108) between 2003 and 2009. The BRAF and NRAS mutation status of the tumors was determined for patients with available tissue samples and the mutation status and clinical characteristics were compared with clinical outcomes...
January 2012: Journal of Immunotherapy
https://read.qxmd.com/read/21984976/high-frequency-of-pik3r1-and-pik3r2-mutations-in-endometrial-cancer-elucidates-a-novel-mechanism-for-regulation-of-pten-protein-stability
#28
JOURNAL ARTICLE
Lydia W T Cheung, Bryan T Hennessy, Jie Li, Shuangxing Yu, Andrea P Myers, Bojana Djordjevic, Yiling Lu, Katherine Stemke-Hale, Mary D Dyer, Fan Zhang, Zhenlin Ju, Lewis C Cantley, Steven E Scherer, Han Liang, Karen H Lu, Russell R Broaddus, Gordon B Mills
We demonstrate that phosphatidylinositol 3-kinase (PI3K) pathway aberrations occur in >80% of endometrioid endometrial cancers, with coordinate mutations of multiple PI3K pathway members being more common than predicted by chance. PIK3R1 (p85α) mutations occur at a higher rate in endometrial cancer than in any other tumor lineage, and PIK3R2 (p85β), not previously demonstrated to be a cancer gene, is also frequently mutated. The dominant activation event in the PI3K pathway appears to be PTEN protein loss...
July 2011: Cancer Discovery
https://read.qxmd.com/read/21946352/exon-capture-analysis-of-g-protein-coupled-receptors-identifies-activating-mutations-in-grm3-in-melanoma
#29
JOURNAL ARTICLE
Todd D Prickett, Xiaomu Wei, Isabel Cardenas-Navia, Jamie K Teer, Jimmy C Lin, Vijay Walia, Jared Gartner, Jiji Jiang, Praveen F Cherukuri, Alfredo Molinolo, Michael A Davies, Jeffrey E Gershenwald, Katherine Stemke-Hale, Steven A Rosenberg, Elliott H Margulies, Yardena Samuels
G protein-coupled receptors (GPCRs), the largest human gene family, are important regulators of signaling pathways. However, knowledge of their genetic alterations is limited. In this study, we used exon capture and massively parallel sequencing methods to analyze the mutational status of 734 GPCRs in melanoma. This investigation revealed that one family member, GRM3, was frequently mutated and that one of its mutations clustered within one position. Biochemical analysis of GRM3 alterations revealed that mutant GRM3 selectively regulated the phosphorylation of MEK, leading to increased anchorage-independent growth and migration...
September 25, 2011: Nature Genetics
https://read.qxmd.com/read/21852383/znf668-functions-as-a-tumor-suppressor-by-regulating-p53-stability-and-function-in-breast-cancer
#30
JOURNAL ARTICLE
Ruozhen Hu, Guang Peng, Hui Dai, Eun-Kyoung Breuer, Katherine Stemke-Hale, Kaiyi Li, Ana M Gonzalez-Angulo, Gordon B Mills, Shiaw-Yih Lin
Genome-wide sequencing studies in breast cancer have recently identified frequent mutations in the zinc finger protein 668 (ZNF668), the function of which is undefined. Here, we report that ZNF668 is a nucleolar protein that physically interacts with and regulates p53 and its negative regulator MDM2. Through MDM2 binding, ZNF668 regulated autoubiquitination of MDM2 and its ability to mediate p53 ubiquitination and degradation. ZNF668 deficiency also impaired DNA damage-induced stabilization of p53. RNA interference-mediated knockdown of ZNF668 was sufficient to transform normal mammary epithelial cells...
October 15, 2011: Cancer Research
https://read.qxmd.com/read/21691666/dynamic-physical-properties-of-dissociated-tumor-cells-revealed-by-dielectrophoretic-field-flow-fractionation
#31
JOURNAL ARTICLE
Sangjo Shim, Peter Gascoyne, Jamileh Noshari, Katherine Stemke Hale
Metastatic disease results from the shedding of cancer cells from a solid primary tumor, their transport through the cardiovascular system as circulating tumor cells (CTCs) and their engraftment and growth at distant sites. Little is known about the properties and fate of tumor cells as they leave their growth site and travel as single cells. We applied analytical dielectrophoretic field-flow fractionation (dFFF) to study the membrane capacitance, density and hydrodynamic properties together with the size and morphology of cultured tumor cells after they were harvested and placed into single cell suspensions...
August 2011: Integrative Biology: Quantitative Biosciences From Nano to Macro
https://read.qxmd.com/read/21621506/biochemical-and-biophysical-characterisation-yields-insights-into-the-mechanism-of-a-cd-zn-transporting-atpase-purified-from-the-hyperaccumulator-plant-thlaspi-caerulescens
#32
JOURNAL ARTICLE
Barbara Leitenmaier, Annelie Witt, Annabell Witzke, Anastasia Stemke, Wolfram Meyer-Klaucke, Peter M H Kroneck, Hendrik Küpper
TcHMA4 (GenBank no. AJ567384), a Cd/Zn transporting ATPase of the P(1B)-type (=CPx-type) was isolated and purified from roots of the Cd/Zn hyperaccumulator Thlaspi caerulescens. Optimisation of the purification protocol, based on binding of the natural C-terminal His-tag of the protein to a Ni-IDA metal affinity column, yielded pure, active TcHMA4 in quantities sufficient for its biochemical and biophysical characterisation with various techniques. TcHMA4 showed activity with Cu(2+), Zn(2+) and Cd(2+) under various concentrations (tested from 30nM to 10μM), and all three metal ions activated the ATPase at a concentration of 0...
October 2011: Biochimica et Biophysica Acta
https://read.qxmd.com/read/21499247/exome-sequencing-identifies-grin2a-as-frequently-mutated-in-melanoma
#33
JOURNAL ARTICLE
Xiaomu Wei, Vijay Walia, Jimmy C Lin, Jamie K Teer, Todd D Prickett, Jared Gartner, Sean Davis, Katherine Stemke-Hale, Michael A Davies, Jeffrey E Gershenwald, William Robinson, Steven Robinson, Steven A Rosenberg, Yardena Samuels
The incidence of melanoma is increasing more than any other cancer, and knowledge of its genetic alterations is limited. To systematically analyze such alterations, we performed whole-exome sequencing of 14 matched normal and metastatic tumor DNAs. Using stringent criteria, we identified 68 genes that appeared to be somatically mutated at elevated frequency, many of which are not known to be genetically altered in tumors. Most importantly, we discovered that TRRAP harbored a recurrent mutation that clustered in one position (p...
May 2011: Nature Genetics
https://read.qxmd.com/read/21490305/pi3k-pathway-mutations-and-pten-levels-in-primary-and-metastatic-breast-cancer
#34
JOURNAL ARTICLE
Ana M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A Barrera, Octavio Burgues, Ana M Lluch, Huiqin Chen, Gabriel N Hortobagyi, Gordon B Mills, Funda Meric-Bernstam
The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy-based approach...
June 2011: Molecular Cancer Therapeutics
https://read.qxmd.com/read/21233401/incidence-and-outcome-of-brca-mutations-in-unselected-patients-with-triple-receptor-negative-breast-cancer
#35
JOURNAL ARTICLE
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun, Gabriel N Hortobagyi, Kim-Anh Do, Gordon B Mills, Funda Meric-Bernstam
PURPOSE: To investigate the incidence of germline and somatic BRCA1/2 mutations in unselected patients with triple-negative breast cancer (TNBC) and determine the prognostic significance of carrying a mutation. METHODS: DNA was obtained from 77 TNBC and normal tissues. BRCA1/2 exons/flanking regions were sequenced from tumor and patients classified as mutant or wild type (WT). Sequencing was repeated from normal tissue to identify germline and somatic mutations...
March 1, 2011: Clinical Cancer Research
https://read.qxmd.com/read/21075308/recombinant-human-erythropoietin-antagonizes-trastuzumab-treatment-of-breast-cancer-cells-via-jak2-mediated-src-activation-and-pten-inactivation
#36
COMMENT
Ke Liang, Francisco J Esteva, Constance Albarracin, Katherine Stemke-Hale, Yang Lu, Giampaolo Bianchini, Ching-Yi Yang, Yong Li, Xinqun Li, Chun-Te Chen, Gordon B Mills, Gabriel N Hortobagyi, John Mendelsohn, Mien-Chie Hung, Zhen Fan
We found that the receptor for erythropoietin (EpoR) is coexpressed with human epidermal growth factor receptor-2 (HER2) in a significant percentage of human breast tumor specimens and breast cancer cell lines. Exposure of HER2 and EpoR dual-positive breast cancer cells to recombinant human erythropoietin (rHuEPO) activated cell signaling. Concurrent treatment of the cells with rHuEPO and trastuzumab reduced the cells' response to trastuzumab both in vitro and in vivo. We identified Jak2-mediated activation of Src and inactivation of PTEN as underlying mechanisms through which rHuEPO antagonizes trastuzumab-induced therapeutic effects...
November 16, 2010: Cancer Cell
https://read.qxmd.com/read/19996208/integrated-molecular-and-clinical-analysis-of-akt-activation-in-metastatic-melanoma
#37
JOURNAL ARTICLE
Michael A Davies, Katherine Stemke-Hale, E Lin, Carmen Tellez, Wanleng Deng, Yennu N Gopal, Scott E Woodman, Tiffany C Calderone, Zhenlin Ju, Alexander J Lazar, Victor G Prieto, Kenneth Aldape, Gordon B Mills, Jeffrey E Gershenwald
PURPOSE: Activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway has been implicated in melanoma based primarily on the prevalence of mutations in PTEN and NRAS. To improve our understanding of the regulation and clinical significance of the PI3K-AKT pathway in melanoma, we quantitatively measured the levels of phosphorylated AKT, its substrate GSK3alpha/beta, and its negative regulator PTEN in clinical metastases. Results were compared with mutational status, clinical outcomes, and sites of metastasis...
December 15, 2009: Clinical Cancer Research
https://read.qxmd.com/read/19671763/activity-of-dasatinib-against-l576p-kit-mutant-melanoma-molecular-cellular-and-clinical-correlates
#38
JOURNAL ARTICLE
Scott E Woodman, Jonathan C Trent, Katherine Stemke-Hale, Alexander J Lazar, Sabrina Pricl, Giovanni M Pavan, Maurizio Fermeglia, Y N Vashisht Gopal, Dan Yang, Donald A Podoloff, Doina Ivan, Kevin B Kim, Nicholas Papadopoulos, Patrick Hwu, Gordon B Mills, Michael A Davies
Point mutations in the KIT receptor tyrosine kinase gene have recently been identified in mucosal, acral lentiginous, and chronically sun-damaged melanomas. We have identified the first human melanoma cell line with an endogenous L576P mutation, the most common KIT mutation in melanoma ( approximately 30-40%). In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors effective in nonmelanoma cells with other KIT mutations...
August 2009: Molecular Cancer Therapeutics
https://read.qxmd.com/read/19573809/akt-independent-signaling-downstream-of-oncogenic-pik3ca-mutations-in-human-cancer
#39
JOURNAL ARTICLE
Krishna M Vasudevan, David A Barbie, Michael A Davies, Rosalia Rabinovsky, Chontelle J McNear, Jessica J Kim, Bryan T Hennessy, Hsiuyi Tseng, Panisa Pochanard, So Young Kim, Ian F Dunn, Anna C Schinzel, Peter Sandy, Sebastian Hoersch, Qing Sheng, Piyush B Gupta, Jesse S Boehm, Jan H Reiling, Serena Silver, Yiling Lu, Katherine Stemke-Hale, Bhaskar Dutta, Corwin Joy, Aysegul A Sahin, Ana Maria Gonzalez-Angulo, Ana Lluch, Lucia E Rameh, Tyler Jacks, David E Root, Eric S Lander, Gordon B Mills, William C Hahn, William R Sellers, Levi A Garraway
Dysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3...
July 7, 2009: Cancer Cell
https://read.qxmd.com/read/19470724/integrative-analysis-of-cyclin-protein-levels-identifies-cyclin-b1-as-a-classifier-and-predictor-of-outcomes-in-breast-cancer
#40
JOURNAL ARTICLE
Roshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, Mark Carey, Ju-Seog Lee, Jens Overgaard, Jan Alsner, Katherine Stemke-Hale, Ana Lluch, Richard M Neve, Wen Lin Kuo, Therese Sorlie, Aysegul Sahin, Vicente Valero, Khandan Keyomarsi, Joe W Gray, Anne-Lise Borresen-Dale, Gordon B Mills, Bryan T Hennessy
PURPOSE: We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling. EXPERIMENTAL DESIGN: The expression levels of cyclins B1, D1, and E1 were quantified in 779 breast tumors and 53 cell lines using reverse phase protein arrays and/or transcriptional profiling. RESULTS: Whereas cyclin E1 overexpression was a specific marker of triple-negative and basal-like tumors, cyclin B1 overexpression occurred in poor prognosis hormone receptor-positive, luminal B and basal-like breast cancers...
June 1, 2009: Clinical Cancer Research
keyword
keyword
78162
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.